Hormone receptor-positive invasive lobular and ductal carcinoma of the breast have comparable hormone receptor expression levels both if detected by screening and clinically

2017 ◽  
Vol 167 (3) ◽  
pp. 817-818
Author(s):  
Alessandra Ravaioli ◽  
Fabio Falcini ◽  
Lauro Bucchi
Keyword(s):  
Hormone Receptor ◽  
Ductal Carcinoma ◽  
Receptor Expression ◽  
Carcinoma Of The Breast ◽  
Expression Levels ◽  
Hormone Receptor Positive ◽  
Hormone Receptor Expression

scholarly journals DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Philipp Jurmeister ◽  
Karsten Weber ◽  
Sonia Villegas ◽  
Thomas Karn ◽  
Michael Untch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Hormone Receptor ◽  
Receptor Expression ◽  
Proliferation Index ◽  
Breast Cancers ◽  
Hormone Receptor Positive ◽  
Dna Methylation Profiling ◽  
Hormone Receptor Expression ◽  
Methylation Profiling

Abstract Background Current clinical guidelines suggest that breast cancers with low hormone receptor expression (LowHR) in 1–10% of tumor cells should be regarded as hormone receptor positive. However, clinical data show that these patients have worse outcome compared to patients with hormone receptor expression above 10%. We performed DNA methylation profiling on 23 LowHR breast cancer specimens, including 13 samples with HER2 amplification and compared our results with a reference breast cancer cohort from The Cancer Genome Atlas to clarify the status for this infrequent but important patient subgroup. Results In unsupervised clustering and dimensionality reduction, breast cancers with low hormone receptor expression that lacked HER2 amplification usually clustered with triple negative breast cancer (TNBC) reference samples (8/10; “LowHR TNBC-like”). In contrast, most specimens with low hormone receptor expression and HER2 amplification grouped with hormone receptor positive cancers (11/13; “LowHR HRpos-like”). We observed highly similar DNA methylation patterns of LowHR TNBC-like samples and true TNBCs. Furthermore, the Ki67 proliferation index of LowHR TNBC-like samples and clinical outcome parameters were more similar to TNBCs and differed from LowHR HRpos-like cases. Conclusions We here demonstrate that LowHR breast cancer comprises two epigenetically distinct groups. Our data strongly suggest that LowHR TNBC-like samples are molecularly, histologically and clinically closely related to TNBC, while LowHR HRpos-like specimens are closely related to hormone receptor positive tumors.

scholarly journals Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Fabio Puglisi ◽  
Lorenzo Gerratana ◽  
Matteo Lambertini ◽  
Marcello Ceppi ◽  
Luca Boni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Effect ◽  
Hormone Receptor ◽  
Recurrence Risk ◽  
Receptor Expression ◽  
Phase Iii ◽  
Composite Measure ◽  
Node Positive ◽  
Hormone Receptor Positive ◽  
Dose Dense

AbstractThe GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6 was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied according to CPRS.

scholarly journals Hormone Receptor Expression Variations in Normal Breast Tissue: Preliminary Results of a Prospective Observational Study

2021 ◽  
Vol 11 (5) ◽  
pp. 387
Author(s):  
Giacomo Santandrea ◽  
Chiara Bellarosa ◽  
Dino Gibertoni ◽  
Maria C. Cucchi ◽  
Alejandro M. Sanchez ◽  
...  
Keyword(s):  
Hormone Receptor ◽  
Breast Tissue ◽  
Normal Breast Tissue ◽  
Normal Breast ◽  
Receptor Expression ◽  
Hormonal Stimulation ◽  
Tissue Samples ◽  
Hormonal Receptor ◽  
Hormone Receptor Expression ◽  
Cystic Disease Fluid Protein

Normal breast tissue undergoes great variations during a woman’s life as a consequence of the different hormonal stimulation. The purpose of the present study was to examine the hormonal receptor expression variations according to age, menstrual cycle, menopausal state and body mass index. To this purpose, 49 tissue samples of normal breast tissue, obtained during surgery performed for benign and malignant conditions, were immunostained with Estrogen (ER), Progesterone (PR) and Androgen receptors (AR). In addition, Ki67 and Gross Cystic Disease Fluid Protein were studied. The data obtained revealed a great variability of hormone receptor expression. ER and AR generally increased in older and post-menopausal women, while young women presented a higher proliferative rate, evaluated with Ki67. PR increase was observed in women with BMI higher than 25. The different hormonal receptor expression could favor the development of breast cancer.

Effects of FSH treatment and withdrawal during proestrus on uterine proliferation and steroid hormone receptor expression in beef heifers

2021 ◽  
Vol 92 (1) ◽  
Author(s):  
Thanya Bunma ◽  
Chutikun Kanjanaruch ◽  
Nattawut Kogram ◽  
Suthipong Uriyapongson ◽  
Vilaivan Khanthusaeng ◽  
...  
Keyword(s):  
Hormone Receptor ◽  
Steroid Hormone ◽  
Receptor Expression ◽  
Steroid Hormone Receptor ◽  
Beef Heifers ◽  
Hormone Receptor Expression
Sign in / Sign up

Export Citation Format

Share Document